Inactive Instrument

Bioheart, Inc. Stock Other OTC

US09062F2011

Biotechnology & Medical Research

End-of-day quote Other OTC Other stock markets
- ^USD	-

23-04-14	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-04-13	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	661 574.61 534.83 491.04 927.3 63.1K 941.66 6.3K 2.47K 31.41K 2.48K 2.43K 105K	P/E 2021	-0.84x	P/E 2022	-0.99x
Enterprise Value	10.08M 8.76M 8.16M 7.49M 14.14M 962M 14.36M 96.14M 37.73M 479M 37.86M 37.02M 1.61B	EV / Sales 2021	59.5x	EV / Sales 2022	160x
Free-Float	89.05%	Yield 2021 *	-	Yield 2022	-

23-04-14	U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-11-09	NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	AQ
22-07-08	U.S. STEM CELL, INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations	AQ
22-05-23	NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	AQ
22-03-31	U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ

Director	Title	Age	Since
William Murphy CHM	Chairman	-	2010-11-01
Miguel Tomás BRD	Director/Board Member	60	2011-08-16
Sheldon Anderson BRD	Director/Board Member	75	2013-08-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+38.10%	+74.02%	56.54B
ARGENX SE	-2.85%	-6.51%	+25.66%	+62.29%	53.6B
BIONTECH SE	+2.45%	+1.40%	-15.61%	-13.72%	22.91B
INSMED INCORPORATED	-0.16%	-7.78%	-9.28%	+352.92%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	+0.36%	+24.28%	-14.44%	20.27B
GENMAB A/S	-1.25%	-2.28%	+31.86%	-29.13%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.15%	+17.96%	+554.50%	14.75B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+162.81%	+287.77%	13.53B
EXELIXIS, INC.	+1.07%	-4.23%	+42.32%	+160.72%	13.33B
Average	-0.14%	-3.78%	+35.34%	+159.44%	25.98B
Weighted average by Cap.	+0.02%	-2.82%	+30.18%	+120.42%

	2021	2022
Net sales	201K 175K 162K 149K 282K 19.16M 286K 1.91M 751K 9.54M 754K 737K 31.99M	82.05K 71.33K 66.39K 60.95K 115K 7.83M 117K 783K 307K 3.9M 308K 301K 13.08M
Net income	-3.29M -2.86M -2.66M -2.44M -4.61M -314M -4.68M -31.35M -12.31M -156M -12.35M -12.08M -524M	-2.86M -2.48M -2.31M -2.12M -4.01M -273M -4.07M -27.26M -10.7M -136M -10.73M -10.5M -455M
Net Debt	8.93M 7.76M 7.22M 6.63M 12.53M 852M 12.72M 85.15M 33.42M 424M 33.53M 32.79M 1.42B	10.08M 8.76M 8.16M 7.49M 14.14M 962M 14.36M 96.13M 37.73M 479M 37.85M 37.02M 1.61B

Bioheart, Inc. Stock Other OTC

Stocks

US09062F2011

Biotechnology & Medical Research

Valuation: Bioheart, Inc.

Latest news : Bioheart, Inc.

Press Releases: Bioheart, Inc.

Managers and Directors: Bioheart, Inc.

Bio Therapeutic Drugs

Financials

Company Profile